Orphan Drug Breakthroughs: Global Acute Intermittent Porphyria...

σε πρόσθεσε στο Öz Farkındalık

2026-03-18 11:51:25 -

Orphan Drug Breakthroughs: Global Acute Intermittent Porphyria Market to reach US$ 7.1 Million by 2034

Acute Intermittent Porphyria (AIP), the most common and severe form of acute hepatic porphyria, is undergoing a clinical shift from reactive crisis management to proactive, genetic-level prevention. Valued at US$ 4.6 Million in 2023, the Global Acute Intermittent Porphyria Market is projected to grow to US$ 7.1 Million by 2034, expanding at a steady CAGR of 3.9%....

0 Σχόλια 0 Μοιράστηκε 225 Views 0 Προεπισκόπηση